



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : SARAH LALDINTLUANGI, Assistant Director (Food and Drugs)
Sr. CMO Office
Serchhip-796181
2. Serial No. and date of Inspector's memorandum : 034/IPA/2025 , 25-FEB-2025
3. Number of Sample : NIL
4. Date of receipt : 17-MAR-2025
5. Names of drugs purporting to be contained in the sample : Cefixime Dispersible Tablets IP 200 mg (NECFIX-200)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/0517	GUW/LS/2025-26/521	CNB24006	May-2024 Apr-2026	NA	Curetech Formulations (P) Ltd., Vill. Juddi Kalan,, Baddi-173 205 Distt. Solan (H.P.)

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 26-May-2025 To 22-Jul-2025

COMPOSITION : Each uncoated dispersible tablet contains:
Cefixime Trihydrate IP eq. to Anhydrous Cefixime 200 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Pink colored, elongated, bi-convex, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Cefixime Trihydrate.	NA
3	Filled Content	0.58392 g	NA
4	Uniformity of weight	Complies.	+5 % of Average weight
5	Disintegration	Complies .(Time taken for disintegration 53 seconds)	NMT 3 minutes

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
-------	-----------------	-------	-------	------------	--------	--------------------

1	Cefixime as Trihydrate equivalent to Anhydrous Cefixime	198.68 mg/Tablet	200 mg/Tablet	99.34	90 % to 110 %	I.P. 2022
---	---	------------------	---------------	-------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 22-JUL-2025

GOVERNMENT ANALYST

Rinku Kalita
Rinku Kalita
Government Analyst
R.D.T.L., Guwahati-22

-----END OF REPORT-----

